GlassScriptPhysician profile
Sarah L Murphy
NPI 1578716213
$3,387.58
in general payments reported to CMS, 2019-2025
33 companies · $695 in 2025
The $695 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $796 · 2023: $765 · 2024: $785 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,244.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $615.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $552.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $434.89 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $268.42 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $192.59 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $122.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $97.24 | 2022-2025 | Spravato |
| Amgen INC. | $92.40 | 2021-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $90.10 | 2021-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $86.29 | 2022-2025 | |
| Pfizer INC. | $67.78 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $65.23 | 2021-2023 | |
| Astellas Pharma US INC | $62.41 | 2022-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.99 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $55.02 | 2023 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $54.60 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $54.57 | 2021-2025 | Verquvo, Lagevrio, Dificid |
| Alnylam Pharmaceuticals INC. | $54.10 | 2025 | Givlaari |
| Sumitomo Pharma America, INC. | $46.51 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.04 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $32.46 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $29.95 | 2023 | Hetlioz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.88 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $24.70 | 2021-2022 | |
| Phadia US INC. | $22.20 | 2023 | Immunocap |
| Shield Therapeutics INC | $20.29 | 2023 | Accrufer |
| Axsome Therapeutics, INC. | $19.94 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $18.15 | 2025 | Voquezna |
| Eisai INC. | $17.63 | 2021 | |
| Abbott Laboratories | $16.49 | 2021 | |
| Esperion Therapeutics, INC. | $16.49 | 2022 | |
| Sage Therapeutics, LLC | $15.37 | 2025 | Zurzuvae |
| Inogen, INC. | $12.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.